Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy

Clinical and Experimental Ophthalmology

Volumn 42, Issue 8, 2014, Pages 769-777

  Gao, Guohong ^a,b   Dai, Jinhui ^a,b   Qian, Yifeng ^a,b   Ma, Fei ^a,b  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Drug therapy; Glucocorticoid; Graves' ophthalmopathy; Meta analysis

Indexed keywords

METHYLPREDNISOLONE; PLACEBO; GLUCOCORTICOID;

CUSHINGOID SYNDROME; DEPRESSION; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYELID RETRACTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; META ANALYSIS; MYALGIA; PATIENT MONITORING; PATIENT SELECTION; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VISUAL ACUITY; WEIGHT GAIN; DRUG PULSE THERAPY; GRAVES OPHTHALMOPATHY; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; RADIOTHERAPY;

ADMINISTRATION, ORAL; COMBINED MODALITY THERAPY; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INFUSIONS, INTRAVENOUS; METHYLPREDNISOLONE; PULSE THERAPY, DRUG; RADIOTHERAPY;

EID: 84911369708     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12317     Document Type: Review

References (50)

1. Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 2012; 96: 311-328.
2. Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest 2010; 33: 414-421.
3. Karoutsou E, Polymeris A. Pathogenesis of Graves' disease focusing on Graves' ophthalmopathy. Endocr Regul 2011; 45: 209-220.
4. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-199.
5. Yang M, Perros P. Management plan and delivery of care in Graves' ophthalmopathy patients. Best Pract Res Clin Endocrinol Metab 2012; 26: 303-311.
6. Anagnostis P, Adamidou F, Polyzos SA etal. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine 2013; 44: 448-453.
7. Zhang C, Zhang X, Ma L, Peng F, Huang J, Han H. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy. Endocrine 2012; 41: 248-255.
8. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves' orbitopathy. J Clin Endocrinol Metab 2012; 97: 3857-3865.
9. Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012; 26: 339-358.
10. Bartalena L, Lai A, Sassi L etal. Novel treatment modalities for Graves' orbitopathy. Pediatr Endocrinol Rev 2010; 7 (Suppl. 2): 210-216.
11. Vannucchi G, Campi I, Bonomi M etal. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 2010; 161: 436-443.
12. Cap J, Ceeova V, Skacha M, Rezek P, Vlcek P, Blaha M. Plasma filtration in the treatment of Graves' ophthalmopathy: a randomized study. J Clin Apher 2010; 25: 209-215.
13. Bartalena L. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 2010; 73: 149-152.
14. Bellis AD, Conzo G, Cennamo G etal. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 2012; 41: 320-326.
15. Kinsell LW, Partridge JW, Foreman N. The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophthalmos. Ann Intern Med 1953; 38: 913-917.
16. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008; 358: 2594-2605.
17. Petrović MJ, Sarenac T, Srećković S, Petrović M, Vulović D, Janićijević K. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment. Vojnosanit Pregl 2012; 69: 249-252.
18. Wichary H, Gasińska T. Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy. Thyroid 2012; 22: 64-69.
19. Gebertt S. Depot-methylprednisolone for subconjunctival and retrobulbar injections. Lancet 1961; 2: 344-345.
20. Ebner R, Devoto MH, Weil D etal. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004; 88: 1380-1386.
21. Nagayama Y, Izumi M, Kiriyama T etal. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 1987; 116: 513-518.
22. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988; 297: 1574-1578.
23. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450-455.
24. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537.
25. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351: 47-52.
26. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
28. Marcocci C, Bartalena L, Tanda ML etal. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86: 3562-3567.
29. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001; 24: 152-158.
30. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90: 5234-5240.
31. Li L, Xiaoli F, Jing X, Wei C, Hongting Z, Fang F. Effects of orbital radiotherapy combined with oral or iv glucocorticoids on the Graves' ophthalmopathy. J Pract Med 2005; 21: 1135-1137.
32. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005; 63: 323-328.
33. Ng CM, Yuen HK, Choi KL etal. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. Hong Kong Med J 2005; 11: 322-330.
34. Aktaran S, Akarsu E, Erbağci I, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy versus oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 2007; 61: 45-51.
35. van Geest RJ, Sasim IV, Koppeschaar HP etal. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008; 158: 229-237.
36. Kauppinen-Mäkelin R, Karma A, Leinonen E etal. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2002; 80: 316-321.
37. Gursoy A, Cesur M, Erdogan MF, Corapcioglu D, Kamel N. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006; 29: 513-516.
38. Owecki M, Sowiński J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy. Pharm World Sci 2006; 28: 73-75.
39. Lendorf ME, Rasmussen AK, Fledelius HC, Feldt-Rasmussen U. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid 2009; 19: 1431-1432.
40. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10: 521.
41. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004; 14: 403-406.
42. Salvi M, Vannucchi G, Sbrozzi F etal. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004; 14: 631-634.
43. Marinò M, Morabito E, Altea MA etal. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005; 28: 280-284.
44. Moli RL, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007; 17: 357-362.
45. Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96: 320-332.
46. Bartalena L, Krassas GE, Wiersinga W etal. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab 2012; 97: 4454-4463.
47. Bartalena L, Baldeschi L, Dickinson A etal. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285.
48. Bartalena L, Baldeschi L, Dickinson AJ etal. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008; 18: 333-346.
49. Abalkhail S, Doi SA, Al-Shoumer KA. The use of corticosteroids versus other treatments for Graves' ophthalmopathy: a quantitative evaluation. Med Sci Monit 2003; 9: 477-483.
50. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009; 94: 2708-2716.